| R |
|
R-138727, the Active Metabolite of Prasugrel (CS-747, LY640315), Inhibits Platelet Aggregation and Thrombus Formation under Blood Flow Conditions
|
| Goto S, Tamura N |
| |
|
Raised Blood Leukocyte Counts Markedly Alter Platelet Aggregation Extent induced by ADP and ATP via CD39
|
| Glenn JR, White AE, Johnson A, Fox SC, Behan MWH, Dolan G, Heptinstall S |
| |
|
Rap1b Is Required for Normal Blood Vessel Formation in Mice
|
| Chrzanowska-Wodnicka M, Kraus AE, McColm J, Geisen P, Cullen J, Hartnett ME, White GC |
| |
|
Rapid Antithrombotic and Anti-platelet Effects of Simvastatin and Micronized Fenofibrate in Patients with Hypercholesterolemia
|
| Celinska-Löwenhoff M, Undas A, Domagala T, Iwaniec T, Dropinski J, Löwenhoff T, Szczeklik A |
| |
|
Ratcheting Between Two Distinct Conformations of Substrate Drives the Sequential Cleavage of Prothrombin by Prothrombinase
|
| Bianchini EP, Orcutt SJ, Krishnaswamy S |
| |
|
Rates of Venous Thromboembolism (VTE) in Californians with Cancer
|
| Wun T, Chew H, Zhou H, Parkh-Patel A, Harvey D, White R |
| |
|
Rational of Pharmacological Effect of a Combination of FVIIa and FX for Hemophilia with Inhibitors
|
| Tomokiyo K, Nakatomi Y, Tsuji M, Nakashima T, Dateki T, Gokudan S, Miyazaki H, Ogata Y, Miyamoto S |
| |
|
Razaxaban, a Novel Direct Factor Xa Inhibitor, Enhanced the Antithrombotic Effects of Aspirin and Clopidogrel But Not Their Bleeding Time Effects in Rabbits
|
| Wong P, Crain E, Quan M, Knabb R, Watson C, Staus A |
| |
|
Reaction of Clot-Bound Thrombin with a Covalent Antithrombin-Heparin Complex Results in an Anticoagulant Surface
|
| Smith LJ, Berry LR, Chan AKC |
| |
|
Reaction of Fibrinogen with Homocysteine Thiolactone Renders the Resulting Fibrin Clots Resistant to Lysis
|
| Sauls DL, Lockhart E, Hoffman M |
| |
|
Real-Time Imaging of Tissue Factor-Positive Microparticles in Flowing Blood
|
| Grabowski EF, Nestoridi E, Kushak RI, Ingelfinger JR |
| |
|
Real-Time in Vivo Imaging of the Kinetics of Macrovascular Thrombus Formation
|
| Bennaghmouch A, Reutelingsperger C, Lindhout T, Bitsch N, Wielders S, Narula J, Hofstra L |
| |
|
Rebound after Discontinuation of Long-term Oral Anticoagulation (OAC): Effects of a 4 week Course of LMWH on VTE Recurrences
|
| Sarif J, Lindhoff-Last E, Bauersachs R |
| |
|
Recent Insights in Adhesion-Dependent Signalling: From the Glycoprotein Ib-IX to the Integrin aIIbb3
|
| Du X |
| |
|
Receptor-mediated Catabolism and Clearance of Factor VIII
|
| Saenko E, Ananyeva N |
| |
|
Receptors, Rafts, and Microvesicles in Thrombosis and Inflammation
|
| López JA, del Conde I, Shrimpton CN |
| |
|
Reciprocal Functional Modulation of von Willebrand Factor A1 Domain and a-Thrombin Bound to Platelet Glycoprotein Iba
|
| Ruggeri ZM |
| |
|
Recombinant Activated Factor VII (rFVIIa, Novoseven®) in Coagulopathic Trauma Patients Significantly Reduces Blood Product Usage: Post-Hoc Subgroup Results from an International, Multi-Centre, Randomised, Placebo-Controlled, Double-Blind, Prospective Clinical Trial
|
| Rizoli S, Riou B, Rossaint R, Kluger Y, Warren B, Lau P, Boffard KD |
| |
|
Recombinant ADAMTS13 Refractory to Suppression by TTP Inhibitors
|
| Zhou W, Motto D, Ginsburg D, Bouhassira E, Tsai H |
| |
|
Recombinant Factor VIIa – Mechanism of Action Based on Dynamic Whole Blood Coagulation Studies
|
| Sørensen B, Ingerslev J |
| |
|
Recombinant Factor VIIa – NovoSeven in Pediatric Practice
|
| Kabakchieva R, Kenderova V, Perenovska P, Kalev I |
| |
|
Recombinant Factor VIIa in the Management of Major Haemorrhage: Use of a Prognostic Scoring System Can Help to Predict Outcome
|
| Biss TT, Hanley JP |
| |
|
Recombinant Factor VIIa Reverses Te Prolonged Bleeding Time Induced B A High Dose of DU-176b, a Novel Direct Factor Xa inhibitor, In Rats
|
| Morishima Y, Honda Y, Matsumoto C, Fukuda T, Isobe K, Kumada T, Shibano T |
| |
|
Recombinant FVIIa Acts in a Tissue Factor Independent Way in a Mouse Model of Hemophilia A
|
| Tranholm M, Kjalke M, Tornehave D, Sørensen BB, Kristensen AT, Røjkjær R |
| |
|
Recombinant Human Albumin Induces Different Coagulation Responses In Vitro Than A Commercial, Purified HAS Formulation
|
| Korte W |
| |
|
Recombinant Tissue Factor (rTF) and Tissue-Plasminogen Activator (t-PA) Used in a Global Assay to Determine Overall Haemostasis Potential (OHP) in Plasma
|
| He S, Margareta B |
| |
|
Recombinant VIIa in Uncontrolled Haemorrhage
|
| Payne E, Laffan M, Brett S |
| |
|
Recurrent Arterial Thrombosis in Patients Taking Aspirin
|
| Cerbone AM, Albisinni R, De Simone C, Macarone Palmieri N, Tufano A, Di Minno M, Arena A, Di Minno G |
| |
|
Recurrent Hemarthroses Halted by Sequential Therapy with Activated Prothrombin Complex Concentrate (aPCC) and Recombinant Factor VIIa
|
| Monahan PE, Gold SH |
| |
|
Recurrent Stroke: The Role of Prothrombotic Disorders
|
| Nowak-Göttl U, Kirkham FJ, Chan AK, Sträter R, Ganesan V, Prengler M, deVeber GA |
| |
|
Recurrent Symptomatic Thrombotic Stroke in Patients with Patent Foramen Ovale and Prothrombin A20210 Mutation or FV Leiden as Potential Thrombophilic Risk Factors
|
| Musso R, Cultrera D, Musso M, Musso A, Cipolla A, Giustolisi R |
| |
|
Recurrent Venous Thromboembolic Events during Treatment with Combined Oral Contraceptives in Hereditaria Dystrophic Epidermolysis Bullosa
|
| Musso R, Cultrera D, Stella M, Musso M, Cipolla A, Giustolisi R |
| |
|
Recurrent Venous Thrombo-Embolism in Cancer Patients: Data from a Hospital-Based Case-Control Study
|
| Descourt R, Le Gal G, Couturaud F, Lacut K, Mottier D, Bressollette L, Leroyer C, Oger E |
| |
|
Red Bloodcell Concentrates Reduces Clot Strength Measured with the Thrombelastograph® (TEG)
|
| Roeloffzen WWH, Bosman L, Kluin-Nelemans JC, de Wolf JThM |
| |
|
Redox-Regulated Coupling of ADP Receptor Signaling and Integrin Function in Platelets
|
| Lahav J, Calo D, Hess O |
| |
|
Reduced Bleeding Achieved through the Encapsulation of a Clot-busting Drug
|
| Leach JK, Thummala A, PattersonO'Rear EEA |
| |
|
Reduced Expression of ABCA1 and A Novel Missense Mutation That Results in Altered Protein Trafficking Underlie Scott Syndrome
|
| Albrecht C, McVey JH, Elliott JI, Sardini A, Kasza I, Mumford AD, Naoumova RP, Tuddenham EGD, Szabo K, Higgins CF |
| |
|
Reduced Fibrin Compaction and Increased Fibrin Formation Rate in Patients with End-Stage Renal Disease
|
| Sjøland JA, Sidelmann JJ, Pedersen RS, Esbensen K, Jespersen J, Gram J |
| |
|
Reduced Platelet Adhesion, Attenuated Atherosclerosis and Increased Resistance to Focal Cerebral Ischemia in Mice Lacking GPIIb Integrin
|
| Schulz C, Schürzinger K, Konrad I, Plesnila N, Rudelius M, Frampton J, Gawaz M, Massberg S |
| |
|
Reduced Thrombus Stability in Mice Lacking the a2A-Adrenergic Receptor
|
| Poz[zcaron]gajová M, Hein L, Nieswandt B |
| |
|
Reduction of Ex Vivo Thrombus Evolution with Anti-Platelet Therapy during Percutaneous Coronary Intervention: The REVEAL Study
|
| Farouque HMO, Andre P, Aggarwal MA, Fearon WF, Lee DP, Phillips DR, Yeung AC |
| |
|
Reduction of Fetal Loss Rate by Anticoagulant Treatment during Pregnancy in Women with Hereditary Deficiency of Antithrombin, Protein C or Protein S Type I. A Prospective Study
|
| Folkeringa N, Brouwer JLP, Korteweg FJ, Veeger NJGM, Erwich JJHM, Holm JP, van der Meer J |
| |
|
Reeavaluation of 75 Patients with Previous Diagnosis of von Willebrand Disease
|
| Sucker C, Zotz RB, Stockschlaeder M, Scharf RE |
| |
|
Re-evaluation of Point-of-Care (POC) Monitors for Routine Oral Anticoagulation Clinic Use
|
| El Rouby S, Heifetz S, Kniessel M-J |
| |
|
References Values of roTEM Instrument
|
| Gafou A, Tsevrenis V, Nomikou E, Bellia M, Theodosiadis G, Paulou E, Andrioti E |
| |
|
Refolding Characteristics of Recombinant Beta3(109-352) Fragment and Formation of a Functionally Active A-Domain
|
| Michalec L, Bledzka-Krupska K, Baltrukovich N, Skurzynski, Sz1 , Cierniewski CS |
| |
|
Regular Plasma Infusion Allows Successful Pregnancy despite Thrombotic Thrombocytopaenic Purpura Relapse in First Trimester
|
| Gunther KE, Smith T |
| |
|
Regulated Shedding of Platelet Receptors Glycoprotein VI and Glycoprotein Ib
|
| Karunakaran D, Gardiner E, Arthur J, Kahn M, Andrews R, Berndt M |
| |
|
Regulation of CD154 (CD40L) and CD62 (p-selectin) Cell Surface Density May Be a Critical Mechanism in Conferring Proinflammatory and Prothrombotic Effects
|
| Chandler B, Kueter TJ, Hansen J, Jennings LK |
| |
|
Regulation of Cell Signaling Pathways by Tissue Factor
|
| Ruf W |
| |
|
Regulation of Human Endothelial Cell Protein C Receptor (hEPCR) Gene Expression
|
| Mollica L, Crawley JTB, Rance JB, Liu K, Wells DJ, Follows GA, Cockerill PN, Lane DA |
| |
|
Regulation of in vivo Viability of Stored Platelet Concentrates by Platelet P-selectin Exposure and Glycoprotein Ib-alpha Downmodulation
|
| Leytin V, Allen D, Mykhaylov S, Freedman J |
| |
|
Regulation of Megakaryocyte Generation by Monocytes/Macrophages
|
| D’Atri LP, Negrotto S, Pozner RG, Landoni VI, Gomez RM, Lazzari MA, Isturiz M, Schattner M |
| |
|
Regulation of Model Thrombus Lysis by TAFIa, PAI-1 and a2-Antiplasmin
|
| Mutch NJ, Thomas L, Moore NR, Booth NA |
| |
|
Regulation of Platelet Guanylyl Cyclase by Collagen: Evidence That Glycoprotein-VI Mediates Platelet Nitric Oxide Synthesis in Response to Collagen
|
| Riba R, Sharifi M, Farndale R, Naseem M |
| |
|
Regulation of Platelet P2Y1 and P2Y12 Purinergic Receptor Internalization
|
| Mundell SJ, Pula G, Hardy AR, Collins J, Conley PB, Poole AW |
| |
|
Regulation of Platelet Receptors
|
| Andrews R, Shen Y, Arthur J, Mu F, Gardiner E, Berndt M |
| |
|
Regulation of Spreading in PECAM-1 Knock-Out Mouse Platelets
|
| Dhanjal TS, McCarty OJT, Ross EA, Buckley CD, Watson SP |
| |
|
Regulation of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Gene Expression in Growth-Promoted Hepatocytes and Role of TAFI in Liver Regeneration
|
| Okumura N, Koh T, Hasebe Y, Watanabe G, Yashiki A, Seno A, Suzuki T, Niimi S, Kawanishi T, Hayakawa T, Seki T, Ariga T |
| |
|
Regulation of Thrombopoiesis
|
| Shivdasani RA |
| |
|
Regulation of Tissue Factor Expression in Brain Microvascular Endothelial Cells by PLA Nanoparticles Loading NF-KappaB Decoy Oligonucleotides
|
| WangHU H-fY, Sun W-q, Xie C-s, Wei W-n |
| |
|
Regulation of Tissue Factor Expression in Human Platelet by Nitric Oxide
|
| Camera M, Frigerio M, Tremoli E |
| |
|
Regulation of Vascular Cell Activation by PECAM-1
|
| Newman PJ |
| |
|
Relation Between Plasmatic Levels of Plasminogen Activator Inhibitor-1 (PAI-1) and Body and Liver Fat Content
|
| de Larrañaga G, Graffigna M, Bendezú K, Belli S, Garcia N, Alonso B, Fainboim H |
| |
|
Relation of Changes in D-dimer and Factor VIIa Levels after Treatment with Heparins to Clinical Outcomes of Unstable Angina
|
| Dobrovolsky A, Ryabysh E, Titaeva E, Fedotkina, Yu, Goltsova K, Panchenko E, Staroverov I |
| |
|
Relationship Among Antibody Against Cytomegalovirus (CMV), Plasma Interleukin-6 (IL-6) and Coronary Artery Disease (CAD) – Preliminary Findings of the Indian Atherosclerosis Research Study (IARS)
|
| Kakkar VV, Rao VS, Natesha B, Kanjilal S, Iyengar SS, Mukherjee M |
| |
|
Relationship Between Circulating Thrombomodulin Levels and Latent: Progression of Atherosclerosis in Type 2 Diabetic Patients
|
| Korzh O, Pavlova E, Lavrova E |
| |
|
Relationship between CYP2C9 and VKORC1 Polymorphisms and Anticoagulant Dose Requirement
|
| Spreafico M, Peyvandi F, Lodigiani C, Mannucci PM |
| |
|
Relationship between Endothelial Haemostatic Markers in Type 2 Diabetic Patients
|
| Korzh O, Lavrova E, Pavlova E |
| |
|
Relationship Between Extrinsic Coagulation Pathway Activation and Metalloproteinase-2/TIMPs System in Hemodialysis Patients
|
| Pawlak K, Pawlak D, Brzosko S, Mysliwiec M |
| |
|
Relationship Between Oxidative Stress, Endothelial Injury and Coagulation: Activation in Advanced Chronic Heart Failure
|
| Korzh I, Fedotova I, Nemtsova V |
| |
|
Relationship of Lipid Rafts and the Platelet Cytoskeleton
|
| Munday AD, Gaus K, Shrimpton CN, Lopéz JA |
| |
|
Relevance of Very Low Titres of Factor VIII Inhibitors in Nijmegen-Bethesda Assay-Negative Patients
|
| Verbruggen HW, Gevers T, Lourenssen GJACM, van Kraaij MGJ, Nováková IRO, van Heerde WL |
| |
|
Reliability and Interobserver Variability of the Simplify® D-Dimer Assay for Detecting D-Dimers in Capillary Blood
|
| Wichers IM, Van der Velde EF, Van Dongen CJ, Van Weert HC, Buller HR, Middeldorp S |
| |
|
Reliability of Platelet Function Analyzer 100 (PFA-100™) Closure Times (CT) Induced by Collagen/Epinephrine (CO/EPI) and by Collagen/ADP (CO/ADP)
|
| Haubelt H, Vogt A, Seyfert UT, Hellstern P |
| |
|
Removal of Hirudin-Like Sequences within the Factor Va Heavy Chain Does Not Impair Prothrombinase Function
|
| Camire RM, Toso R, Zhu H |
| |
|
Removal of PrPSc in the Manufacturing Process of OCTAPLAS and UNIPLAS
|
| Biesert L, Schmidt T, Heger A, Seeger H, Aguzzi A |
| |
|
Reproducibility and Utility of a Flow Cytometric-Based Annexin V Competition Assay for Evaluation of the Antiphospholipid Syndrome
|
| Webber B, Nolen JDL, Duncan A |
| |
|
Reproducibility of the Endogenous Thrombin Potential by Calibrated Automated Thrombogram Assay
|
| van Veen JJ, Cooper PC, Kitchen S, Makris M |
| |
|
Reproductive Choices, Pregnancies and Deliveries in Carriers of Hemophilia – Results of the CarrierQOL-Study
|
| C Wermes, I Wieland, R Eisert, A Ganser |
| |
|
Residual Anticoagulant Activity Following Bridging Low Molecular Weight Heparin: Prevalence and Risk Factors
|
| O'Donnell MJ, Kearon C, Johnson J, Turpie ID, Zondag M, Robinson M, Turpie AGG |
| |
|
Residual Vein Thrombosis Assessment Establishes the Optimal Duration of Oral Anticoagulants in Patients with Idiopathic or Provoked Deep Vein Thrombosis: a Randomized, Controlled Trial
|
| Siragusa S, Malato A, Anastasio R, Milio G, Bonifacio G, Dolce A, Mariani G |
| |
|
Resistance to Activated Proteine C (aPCR) in Subjects ‘Negative’ for Factor V Leiden (FVL) and ‘Positive’ for Antiphospholipid Antibodies (APL)
|
| Ghirarduzzi A, Scamardella F, Albertazzi L, Maconi M, Accardo PA, Iotti M, Bonacini N, Brini M |
| |
|
Resolution of Pulmonary Thrombo-embolism in Patients with Pulmonary Embolism; A Systematic Review
|
| Nijkeuter M, Hovens MMC, Huisman MV |
| |
|
Responsiveness to Desmopressin: Influence of Genotype in Patients Diagnosed with Type 1 von Willebrand Disease in the European Study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD
|
| Lethagen S, Castaman G, Federici A, Mazurier C, Eikenboom J, Schneppenheim R, Ingerslev J, Makris M, Vorlova Z, Peake I, Goodeve A, Rodeghiero F, Batlle J, Meyer D, Goudemand J, Budde U, Habart D, Holmberg L, Pasi J, Hill F |
| |
|
Results from the Canadian Hemophilia Dose Escalation Prophylaxis Trial: An Update
|
| Blanchette V, Rivard G, Israels S, Robinson S, Babyn P, Oh P, Einarson T, McLimont M, Stain A, Hilliard P, Feldman B |
| |
|
Results of ‘Home Treatment’ for Patients with Using Factor VIII Concentrate ‘Hemoctin STD’
|
| Plyushch OP, Zozulya NI, Kopylov KG |
| |
|
Results of the Master Lot Calibration of a New Coagulation Monitoring System for Patient Self Testing
|
| Leichsenring I, Plesch W, Unkrig V, Newhart A, Kitchen S, Kitchen DP, Mclean R, Dikkeschei B, van den Besselaar AMHP |
| |
|
Resuscitation with Lactated Ringers (LR) vs. Normal Saline (NS) Leads to a Hypercoagulable State in an Uncontrolled Hemorrhagic Shock Swine Model
|
| Wiesberg TT, Differding JA, Enomoto TM, Sawai RS, Muller PJ, Hagg D, Phillips C, Diggs B, Schreiber MA |
| |
|
Retinal Vein Occlusion and Anticoagulation: Does It Offer Any Benefit? Report of Two Cases
|
| Meschengieser SS, Lazzari MA |
| |
|
Retrospective and Prospective Analysis of the Incidence of Venous Thromboembolism in First-Degree Relatives of Factor V Leiden and Factor II G20210A Carriers
|
| Oliveira LCO, Rizzatti EG, Inácio RAS, Baggio MS, Tavella MH, Franco RF |
| |
|
Retrospective Calculation of the Modified Wells' Clinical Probability of Pulmonary Embolism: Agreement with Prospective Scoring
|
| Hogg K, Dawson D, Teece S, Mackway-Jones K |
| |
|
Retrospective Open Multicenter Study on the Efficacy and Safety of Activated Prothrombin Complex (Feiba®) in Haemorrhage and Surgical Interventions in Haemophilia Patients with Inhibitor and in Patients with Rare Bleeding Disorders in Turkey
|
| Zulfikar B, Kavakli K, Dundar S, Aydogan G, Oner AF, Gursel T, Zulfikar H, Akbulut A |
| |
|
Retrospective Study of 41 Patients Homozygous for the Prothrombin G20210A Mutation
|
| Juin F, Flaujac C, Horellou MH, Elalamy I, Samama MM, Conard J |
| |
|
Retrospective Study on Thrombosis in Japanese Children
|
| Ohi C, Yamashita A, Taki M |
| |
|
Reversal of the Inhibitory Effect of Monclonal Antiphospholipid Antibodies on Trophoblast Proliferation by Unfractionated Heparin, Low Molecular Weight Heparins (Enoxaparin and Dalteparin) and a Synthetic Pentasaccharide, Fondaparinux
|
| McLintock C, Chamley L, Stone P |
| |
|
rFVIIa (NovoSeven®) for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients with Inhibitors: A Double-Blind Study of a Single High Dose Versus Standard Multiple Doses of rFVIIa
|
| Kavakli K, Makris M, Zulfikar B, Abrams Z, Kenet G |
| |
|
Rho Kinase Regulates Platelet Adhesion and Aggregation on Collagen under Flow
|
| Calaminus SDJ, Auger JM, McCarty OJT, Wakelam MJO, Watson SP |
| |
|
Right Ventricular Dysfunction and the Pulmonary Obstruction Index Assessed with Helical CT Predict Clinical Outcome During Three-month Follow-up in Patients with Acute Pulmonary Embolism
|
| Huisman MV, van der Meer RW, van Strijen MJL, Pattynama PMT, de Roos A |
| |
|
Risk Factor Assessment in the Management of Patients with Suspected Deep Venous Thrombosis
|
| Jalali F, Haghighi N, Swift P |
| |
|
Risk Factors for Central Retinal Vein Occlusion
|
| MacCallum PK, Cooper JA, Sheikh H, Howarth DJ, Galton DJ, Meade TW |
| |
|
Risk Factors for Chemotherapy-Associated Venous Thromboembolism in a Prospective Observational Study: A Proposed Predictive Model
|
| Khorana AA, Francis CW, Culakova E, Lyman GH |
| |
|
Risk Factors for CVC-Associated Thrombosis in Cancer Patients: Analysis of the ETHIC Study
|
| Verso M, Agnelli G, Kamphuisen PW, Bertoglio S, Ageno W, Bazzan M, Parise P, Quintavalla R, Naglieri E, Santoro A, Imberti D, Sorarù M, for the ETHICS Investigators |
| |
|
Risk Factors for the Postthrombotic Syndrome (PTS)
|
| Stain M, Schönauer V, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Kyrle P, Eichinger S |
| |
|
Risk Factors for Thrombophilia in Extra-Hepatic Portal Vein Obstruction
|
| Martinelli I, Bucciarelli P, Battaglioli T, Primignani M, Mannucci PM |
| |
|
Risk Factors for Venous Thromboembolism (VTE) among Patients Hospitalized for Acute Medical Illness: A Population-Based Case-Control Study
|
| Heit JA, Petterson TM, Bailey KR, Melton III LJ |
| |
|
Risk Factors for Venous Thromboembolism (VTE) Among Patients Hospitalized for Major Surgery: A Population-Based Case-Control Study
|
| Heit JA, Petterson TM, Bailey KR, Melton LJ, III |
| |
|
Risk Factors for Venous Thrombosis in Swedish Children and Adolescents
|
| Rask O, Berntorp E, Ljung R |
| |
|
Risk Factors for VTE In Patients Undergoing Abdominal Surgery: Lessons from the PEGASUS Trial
|
| Bergqvist D, Agnelli G, Cohen AT, Gallus AS, Gent M |
| |
|
Risk of a First Episode of Venous Thromboembolism (VTE) in First Degree Relatives of Patients with an Acute Episode of VTE in Association with Factor V Leiden
|
| Couturaud F, Descourt R, Le Gall G, Lacut K, Oger E, Gutgobert C, Abgrall JF, Treguer G, Blouch MT, Leroyer C, Mercier B, Ferec C, Mottier D |
| |
|
Risk of a First Episode of Venous Thromboembolism (VTE) in First Degree Relatives of Patients with an Acute Episode of VTE in Association with Factor V Leiden: An Analysis According to Age of Patients
|
| Couturaud F, Le Gall G, Lacut K, Oger E, Descourt R, Gutgobert C, Abgrall JF, Treguer G, Blouch MT, Leroyer C, Mercier B, Ferec C, Mottier D |
| |
|
Risk of Arterial Thrombosis in Carriers of a Familial Thrombophilic Defect
|
| Vossen CY, Conard J, Fontcuberta J, de Jonge I, Makris M, van der Meer FJM, Pabinger I, Palareti G, Preston FE, Scharrer I, Souto JC, Svensson P, Walker ID, Rosendaal FR |
| |
|
Risk of Deep Vein Thrombosis in Carriers of Factor V Leiden: Case-Controls vs Cohort Studies
|
| Wu O, Robertson L, Lowe GDO |
| |
|
Risk of Recurrent Venous Thromboembolism (VTE) Associated with Hereditary Deficiencies of Protein C, Protein S and Antithrombin Depends on Cosegregation with Other Thrombophilic Disorders: A Prospective Family Cohort Study
|
| Brouwer JLP, Ten Kate MK, Veeger NJGM, Van der Schaaf W, Kluin-Nelemans HC, Van der Meer J |
| |
|
Risk of Recurrent Venous Thromboembolism Associated with Inherited Deficiency of Natural Anticoagulants
|
| De Stefano V, Simioni P, Rossi E, Tormene D, Za T, Pagnan A, Leone G |
| |
|
Risk of Recurrent Venous Thromboembolism in Children with Cerebral Venous Thrombosis – A Prospective Follow-Up Cohort Study
|
| Nowak-Göttl U, Bidlingmaier C, Heller C, Knöfler R, Schobess R, Zieger BDu¨ringC, Sträter R, Kurnik K |
| |
|
Risk of Thromboembolic Events and Major Bleeding in Patients Treated with Vitamin K Antagonists after Heart Valve Replacement (HVR); Individual Time within Target Range (ITTR) an Accurate Predictor
|
| Veeger NJGM, Hillege HL, Piersma-Wichers M, van der Meer J |
| |
|
Risk of Venous Thromboembolism (VTE) Related to first Pregnancy in At-Deficient Women. One-Center Study of 43 Pregnant Women without Prophylaxis
|
| Conard J, Mathieux V, Plu-Bureau G, Horellou MH, Elalamy I, Samama MM |
| |
|
Ristocetin Accelerates Von Willebrand Factor (VWF) Hydrolysis Rate and Ameliorates Collagen Binding Assay (CBA) Sensitivity
|
| Palla R, De Cristofaro R, Peyvandi F, Mannucci PM |
| |
|
Ristocetin Cofactor (VWF:Rco) Assay – A Comparison of a Rapid Automated Method on ACL10000 Coagulometer and Conventional Aggregometry
|
| Sakthivel MSM, Nair SC, Mammen JJ, Singh S, Sukumaran D, Srivastava A |
| |
|
Rituximab in the Treatment of FXIII Inhibitor Possibly Caused by Ciprofloxacin
|
| Miesbach W, Boehm M, Scharrer I |
| |
|
Rituximab Treatment of FVIII Inhibitors in Congenital Hemophilia A (cHA)
|
| Pruthi RK, Schmidt KA, Slaby JA, Hook CC, Nichols WL |
| |
|
RNA Interference Targeting Tissue Factor in a Murine Melanoma Metastasis Model
|
| Wiiger MT, Vasovic V, Peng Q, Nesland JM, Prydz H |
| |
|
Robustness Testing of OPTIVATE® Intermediate Purification Stages
|
| Lloyd J, Marshall PJ, Li Z, Burman H, Bansal K |
| |
|
Rofecoxib (Vioxx) Increases Thrombin Generation in Platelet Rich Plasma
|
| Al Dieri R, Van der Heijde D, Van der Linden S, Woodhams B, Béguin S, Hemker HC |
| |
|
Role of Chloride Ions in the Modulation of the Interaction between von Willebrand Factor and Adamts-13
|
| De Cristofaro R, Palla R, Peyvandi F, Lavoretano S, Lombardi R, Merati G, Di Stasio E, Mannucci PM |
| |
|
Role of Endothelial Cell-Derived Microparticles in Patients with Chronic Heart Failure
|
| Korzh O, Krasnokutskiy S |
| |
|
Role of Endothelial Dysfunction Effect on Coagulation Haemostases in Patients with Chronic Heart Failure
|
| Mirsamatova G |
| |
|
Role of FcRg and FXIII in Coated Platelet Formation and Platelet Procoagulant Activity in Mice
|
| Shawn MJ, Lorie L, Gerhard D, Steven RL, Jorge DP |
| |
|
Role of Gamma-Carboxyglutamic Acid (Gla) and First Epidermal Growth Factor (EGF1)-Like Domains of Factor IX (FIX) in Physiologic Coagulation
|
| Ndonwi M, Broze G, Bajaj Jr. SP |
| |
|
Role of GPIb, GPIIb/IIIa and Shear on COAT-Platelets Formation
|
| Meier R, Colucci G, Pontiggia L, Clemetson KJ, Alberio L |
| |
|
Role of Human Polymorphonuclear Neutrophils in Endothelial Cell Damage Induced by Shiga Toxin-1 and Inflammatory Agents
|
| Landoni V, Negrotto S, D'Atri P, Ramos V, Fernández G, Palermo M, Schattner M, Isturiz M |
| |
|
Role of Integrin a2b1 in Thrombus Stabilization and Embolization
|
| Kuijpers MJE, Grüner S, Munnix ICA, Pozgajova M, Auger JM, Eckes B, Nieswandt B, Heemskerk JWM |
| |
|
Role of Isoleucine Residues 182 and 183 in Thrombin-Activatable Fibrinolysis Inhibitor
|
| Marx PF, Havik SR, Bouma BN, Meijers JCM |
| |
|
Role of Periodontal Pathogens in Coronary Artery Disease in Saudis
|
| Al-Mutairi M, Arfin M, Rizvi S, Tariq M |
| |
|
Role of Phospholipids in the Activation of F.X By Tissue Factor : VIIa
|
| Hathcock JJ, Rusinova E, Heikki Vanannan, Nemerson Y |
| |
|
Role of Plasma Exchange (PE) in the Treatment of Transplant-Associated Thrombotic Microangiopathy (TM)
|
| Ashrani AA, McCullough J, Gibson C, Key NS |
| |
|
Role of Platelet Aggregation Testing in Acute Stent Thrombosis
|
| Remijn JA, Smit JJJ, van't Hof AWJ, Dambrink JHE, Slingerland RJ |
| |
|
Role of Residue 192 in Development of the Oxyanion Hole and in Macromolecular Specificity in Serine Proteases: Importance of Lys554 (192 in Chymotrypsin Numbering) in Factor XIa Catalysis
|
| Schmidt AE, Sun MF, Rodriguez W, Gailani D, Bajaj SP |
| |
|
Role of Residue 193 in Development of the Oxyanion Hole in Serine Proteases: Kinetic Studies of the Effect of Side Chain Length and Charge in Factor XIa
|
| Schmidt AE, Sun MF, Ogawa T, Gailani D, Bajaj SP |
| |
|
Role of the Bile Salt Dependent Lipase (BSDL) in Thrombus Formation: in vitro and in vivo Study
|
| Panicot-Dubois L, Dubois C, Furie BC, Furie B, Lombardo D |
| |
|
Role of the Fibrinolytic System in the Development of Obesity and the Metabolic Syndrome
|
| Juhan-Vague I, Alessi MC, Lijnen R |
| |
|
Role of the Matrix Metalloproteinase System in Adipose Tissue Development
|
| Lijnen HR |
| |
|
Role of the Platelet P2Y1 Receptor in Thrombus Formation Under Flow Conditions
|
| Marchese P, Almus-Jacobs F, Cattaneo M, Gachet C, Ruggeri ZM |
| |
|
Role of the Protein C System in Endothelial and Breast Cancer Cell Migration
|
| Beaulieu LM, Church FC |
| |
|
Role of the Thrombin Receptor (PAR-1) in the Regulation of Menstrual Bleeding
|
| Edlund M, Andersson E |
| |
|
Role of Thrombin Formed on the Surface of Activated Platelets on the Three-Dimensional Growth of Platelet Thrombi Formed on the Collagen Fibrils under Blood Flow Conditions
|
| Tamura N, Goto S |
| |
|
Roles of Adhesion Molecules in the Development of Antiphospholipid Syndrome: Key Roles of E-selectin in the Induction of Antiphospholipid Antibodies
|
| Yamazaki M, Asakura H, Nakao S |
| |
|
Roles of Arg257 and Arg1176 of ADAMTS13 in Its Proteolysis and Its Activity against VWF
|
| Lam JK, Chan , Kwo Chion A, Crawley JTB, Lane DA |
| |
|
Roles of Platelet ADP and Gas6 Receptors in Thrombus Stability
|
| Cosemans JMEM, Munnix ICA, Angelillo-Scherrer A, Carmeliet P, Heemskerk JWM |
| |
|
Rosuvastatin Reduces Platelet Activation in Heart Failure: Role of Nitric Oxide Bioavailability
|
| Schäfer A, Fraccarollo D, Eigenthaler M, Tas P, Frantz S, Walter U, Ertl G, Bauersachs J |
| |
|
Rotation Thrombelstography Monitoring during Liver Transplantation
|
| Stancheva A, Boncheva M, Koleva V |
| |
|
Rotation Thromboelastometry in Patients Receiving Platelet Transfusion after Chemotherapy
|
| Dehmel H, Eisert R, Horter S, Ganser A, Tiede A |
| |
|
Routine Use of Oral Vitamin K for the Reversal of Anticoagulation with Warfarin in Patients Scheduled for Elective Procedures
|
| Thienelt CD, Woodhouse GM, Hassell KL |
| |
